Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD)....
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Atlantis Press
2019-08-01
|
Series: | Clinical Hematology International |
Subjects: | |
Online Access: | https://www.atlantis-press.com/article/125917032/view |
id |
doaj-9f5036f957754af48cd575ee99d16d39 |
---|---|
record_format |
Article |
spelling |
doaj-9f5036f957754af48cd575ee99d16d392020-11-25T01:43:46ZengAtlantis PressClinical Hematology International2590-00482019-08-011410.2991/chi.d.190823.001Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell TransplantationZachariah DeFilippNalu Navarro-AlvarezShuli LiAlec R. AndrewsAriel JohnsonYi-Bin ChenVincent T. HoJerome RitzThomas R. SpitzerChristene A. HuangGalectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5–61.6), which was significantly higher than that among healthy controls (14.9 versus 6.2, p < 0.001). Furthermore, patients with active cGVHD at the time of sample collection had higher median levels as compared to those without cGVHD (16.9 versus 13, p = 0.03). In a multivariable logistic model, there was no significant association between the presence of cGVHD at the date of sample collection and elevated galectin-3 levels (>14.9 ng/mL) (odds ratio [OR]: 2.03 (0.60, 6.88), p = 0.26). However, among patients with cGVHD at the date of sample collection, active systemic corticosteroid therapy was associated with elevated galectin-3 levels (OR: 20.32 (1.66, 249.39), p = 0.02). Furthermore, in a competing risk regression model, elevated galectin-3 levels at 1 year post-HCT were not associated with future development of moderate or severe cGVHD (OR: 1.24 (0.21, 7.45), p = 0.81). In conclusion, plasma galectin-3 concentrations are elevated in recipients of allo-HCT, especially among patients with cGVHD. Further investigation will be required to determine whether galectin-3 has a pathophysiologic role in cGVHD or serves as a marker of ongoing inflammation following allogeneic HCT.https://www.atlantis-press.com/article/125917032/viewGalectin-3Chronic graft-versus-host diseaseAllogeneic hematopoietic cell transplantation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zachariah DeFilipp Nalu Navarro-Alvarez Shuli Li Alec R. Andrews Ariel Johnson Yi-Bin Chen Vincent T. Ho Jerome Ritz Thomas R. Spitzer Christene A. Huang |
spellingShingle |
Zachariah DeFilipp Nalu Navarro-Alvarez Shuli Li Alec R. Andrews Ariel Johnson Yi-Bin Chen Vincent T. Ho Jerome Ritz Thomas R. Spitzer Christene A. Huang Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation Clinical Hematology International Galectin-3 Chronic graft-versus-host disease Allogeneic hematopoietic cell transplantation |
author_facet |
Zachariah DeFilipp Nalu Navarro-Alvarez Shuli Li Alec R. Andrews Ariel Johnson Yi-Bin Chen Vincent T. Ho Jerome Ritz Thomas R. Spitzer Christene A. Huang |
author_sort |
Zachariah DeFilipp |
title |
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation |
title_short |
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation |
title_full |
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation |
title_fullStr |
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation |
title_full_unstemmed |
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation |
title_sort |
elevated galectin-3 plasma concentrations in recipients of allogeneic hematopoietic cell transplantation |
publisher |
Atlantis Press |
series |
Clinical Hematology International |
issn |
2590-0048 |
publishDate |
2019-08-01 |
description |
Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5–61.6), which was significantly higher than that among healthy controls (14.9 versus 6.2, p < 0.001). Furthermore, patients with active cGVHD at the time of sample collection had higher median levels as compared to those without cGVHD (16.9 versus 13, p = 0.03). In a multivariable logistic model, there was no significant association between the presence of cGVHD at the date of sample collection and elevated galectin-3 levels (>14.9 ng/mL) (odds ratio [OR]: 2.03 (0.60, 6.88), p = 0.26). However, among patients with cGVHD at the date of sample collection, active systemic corticosteroid therapy was associated with elevated galectin-3 levels (OR: 20.32 (1.66, 249.39), p = 0.02). Furthermore, in a competing risk regression model, elevated galectin-3 levels at 1 year post-HCT were not associated with future development of moderate or severe cGVHD (OR: 1.24 (0.21, 7.45), p = 0.81). In conclusion, plasma galectin-3 concentrations are elevated in recipients of allo-HCT, especially among patients with cGVHD. Further investigation will be required to determine whether galectin-3 has a pathophysiologic role in cGVHD or serves as a marker of ongoing inflammation following allogeneic HCT. |
topic |
Galectin-3 Chronic graft-versus-host disease Allogeneic hematopoietic cell transplantation |
url |
https://www.atlantis-press.com/article/125917032/view |
work_keys_str_mv |
AT zachariahdefilipp elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT nalunavarroalvarez elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT shulili elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT alecrandrews elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT arieljohnson elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT yibinchen elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT vincenttho elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT jeromeritz elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT thomasrspitzer elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation AT christeneahuang elevatedgalectin3plasmaconcentrationsinrecipientsofallogeneichematopoieticcelltransplantation |
_version_ |
1725031696281108480 |